UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ...

(MENAFN- GlobeNewsWire - Nasdaq) Rheumatologists' perceptions of Bimzelx outperform analogue launches of Rinvoq, Skyrizi, and Tremfya in psoriatic arthritis at the three months post-launch mark ...

EXTON, PA, Feb. 13, 2025 (GLOBE NEWSWIRE) -- UCB’s Bimzelx (bimekizumab) is making a strong entrance into the U.S. psoriatic ... and Skyrizi, and JNJ Innovative Medicine’s Tremfya in PsA ...

EXTON, PA, Feb. 13, 2025 (GLOBE NEWSWIRE) -- UCB’s Bimzelx (bimekizumab) is making a strong entrance into the U.S. psoriatic arthritis ... including AbbVie’s Rinvoq and Skyrizi, and JNJ Innovative ...

Psoriasis was less likely to progress to psoriatic arthritis (PsA) among patients treated with interleukin-17 (IL-17) or ...

“Psoriatic arthritis is a complex disease ... Some analysts meanwhile have suggested Tremfya’s biggest challenge will be to stay ahead of Skyrizi, which has been proposed as a ‘best-in ...

Crohn's the third indication for Skyrizi after psoriasis and psoriatic arthritis, and a key step ... J&J has phase 2 results in hand with Tremfya in Crohn's, but Lilly's mirikizumab is closest ...

Psoriatic Arthritis, Crohn's Disease, and Ulcerative Colitis for Skyrizi, and Rheumatoid Arthritis, Psoriatic Arthritis, Atopic Dermatitis, Ulcerative Colitis, Crohn's Disease, Ankylosing ...

So, in the case of AbbVie, they said that biosimilar Humira has actually driven a volume shift in favor of other brands like Skyrizi ... with Tremfya in psoriasis and psoriatic arthritis, but ...